Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

41 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study.
Bromberg JEC, Issa S, Bakunina K, Minnema MC, Seute T, Durian M, Cull G, Schouten HC, Stevens WBC, Zijlstra JM, Baars JW, Nijland M, Mason KD, Beeker A, van den Bent MJ, Beijert M, Gonzales M, de Jong D, Doorduijn JK. Bromberg JEC, et al. Among authors: seute t. Lancet Oncol. 2019 Feb;20(2):216-228. doi: 10.1016/S1470-2045(18)30747-2. Epub 2019 Jan 7. Lancet Oncol. 2019. PMID: 30630772 Clinical Trial.
Health-related quality of life and cognitive functioning in long-term anaplastic oligodendroglioma and oligoastrocytoma survivors.
Habets EJ, Taphoorn MJ, Nederend S, Klein M, Delgadillo D, Hoang-Xuan K, Bottomley A, Allgeier A, Seute T, Gijtenbeek AM, de Gans J, Enting RH, Tijssen CC, van den Bent MJ, Reijneveld JC. Habets EJ, et al. Among authors: seute t. J Neurooncol. 2014 Jan;116(1):161-8. doi: 10.1007/s11060-013-1278-0. Epub 2013 Oct 26. J Neurooncol. 2014. PMID: 24162809
Neurocognitive functioning and radiologic changes in primary CNS lymphoma patients: results from the HOVON 105/ALLG NHL 24 randomized controlled trial.
van der Meulen M, Dirven L, Habets EJJ, Bakunina K, Smits M, Achterberg HC, Seute T, Cull G, Schouten H, Zijlstra JM, Brandsma D, Enting RH, Beijert M, Taphoorn MJB, van den Bent MJ, Issa S, Doorduijn JK, Bromberg JEC. van der Meulen M, et al. Among authors: seute t. Neuro Oncol. 2021 Aug 2;23(8):1315-1326. doi: 10.1093/neuonc/noab021. Neuro Oncol. 2021. PMID: 33560442 Free PMC article. Clinical Trial.
Extent of radiological response does not reflect survival in primary central nervous system lymphoma.
van der Meulen M, Postma AA, Smits M, Bakunina K, Minnema MC, Seute T, Cull G, Enting RH, van der Poel M, Stevens WBC, Brandsma D, Beeker A, Doorduijn JK, Issa S, van den Bent MJ, Bromberg JEC. van der Meulen M, et al. Among authors: seute t. Neurooncol Adv. 2021 Feb 15;3(1):vdab007. doi: 10.1093/noajnl/vdab007. eCollection 2021 Jan-Dec. Neurooncol Adv. 2021. PMID: 33615224 Free PMC article.
Survival, neurocognitive function, and health-related quality of life outcomes after rituximab-methotrexate, BCNU, teniposide, and prednisolone for primary CNS lymphoma: Final results of the HOVON 105/ALLG NHL 24 study.
Bromberg JEC, Issa S, van der Holt B, van der Meulen M, Dirven L, Minnema MC, Seute T, Durian M, Cull G, van der Poel MWM, Stevens WBC, Zijlstra JM, Brandsma D, Nijland M, Mason KD, Beeker A, Abrahamse-Testroote MCJ, van den Bent MJ, de Jong D, Doorduijn JK. Bromberg JEC, et al. Among authors: seute t. Neuro Oncol. 2024 Apr 5;26(4):724-734. doi: 10.1093/neuonc/noad224. Neuro Oncol. 2024. PMID: 38037691 Free PMC article. Clinical Trial.
41 results